$359 Million is the total value of Tamarack Advisers, LP's 33 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 45.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| DGX | Sell | QUEST DIAGNOSTICS INCequity | $31,339,000 | +23.1% | 275,000 | -13.2% | 8.72% | -9.5% |
| HOLX | Sell | HOLOGIC INCequity | $18,525,000 | +38.9% | 325,000 | -14.5% | 5.16% | +2.1% |
| NUAN | Sell | NUANCE COMMUNICATIONS INCequity | $14,550,000 | +38.7% | 575,000 | -8.0% | 4.05% | +2.0% |
| MDT | Sell | MEDTRONIC PLCequity | $13,755,000 | -32.2% | 150,000 | -33.3% | 3.83% | -50.2% |
| BIO | Sell | BIO-RAD LABORATORIES-Aequity | $13,545,000 | -3.4% | 30,000 | -25.0% | 3.77% | -29.0% |
| OPTN | Sell | OPTINOSE INCequity | $11,346,000 | +63.0% | 1,525,000 | -1.6% | 3.16% | +19.8% |
| MDRX | Sell | ALLSCRIPTS HEALTHCARE SOLUTIequity | $10,832,000 | -45.2% | 1,600,000 | -43.1% | 3.02% | -59.7% |
| ATRC | Sell | ATRICURE INCequity | $10,114,000 | -49.8% | 225,000 | -62.5% | 2.82% | -63.1% |
| MYL | Sell | MYLAN NVequity | $6,432,000 | -52.1% | 400,000 | -55.6% | 1.79% | -64.8% |
| ISEE | Sell | IVERIC BIO INCequity | $5,100,000 | +18.6% | 1,000,000 | -20.0% | 1.42% | -12.8% |
| SIBN | Sell | SI-BONE INCequity | $1,677,000 | -32.2% | 105,200 | -49.2% | 0.47% | -50.2% |
| ITGR | Exit | INTEGER HOLDINGS CORPequity | $0 | – | -10,000 | -100.0% | -0.24% | – |
| PODD | Exit | INSULET CORPequity | $0 | – | -5,000 | -100.0% | -0.31% | – |
| EHTH | Exit | EHEALTH INCequity | $0 | – | -10,000 | -100.0% | -0.53% | – |
| EW | Exit | EDWARDS LIFESCIENCES CORPequity | $0 | – | -10,000 | -100.0% | -0.71% | – |
| PFE | Exit | PFIZER INCequity | $0 | – | -100,000 | -100.0% | -1.24% | – |
| BDX | Exit | BECTON DICKINSON AND COequity | $0 | – | -15,000 | -100.0% | -1.30% | – |
| PGNX | Exit | PROGENICS PHARMACEUTICALSequity | $0 | – | -1,100,000 | -100.0% | -1.58% | – |
| MRK | Exit | MERCK & CO. INC.equity | $0 | – | -90,000 | -100.0% | -2.62% | – |
| CHNG | Exit | CHANGE HEALTHCARE INCequity | $0 | – | -700,000 | -100.0% | -2.65% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-11
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VERADIGM ORD | 32 | Q3 2023 | 13.9% |
| STREAMLINE HEALTH SOLUTIONS ORD | 30 | Q3 2023 | 4.0% |
| ATRICURE ORD | 29 | Q3 2023 | 7.6% |
| PACIRA PHARMACEUTICALS INC | 27 | Q1 2023 | 12.1% |
| LANTHEUS HOLDINGS ORD | 25 | Q4 2022 | 9.6% |
| MEDTRONIC PLC | 21 | Q1 2022 | 12.7% |
| RIGEL PHARMACEUTICALS ORD | 21 | Q2 2023 | 8.0% |
| BIO RAD LABORATORIES CL A ORD | 19 | Q2 2023 | 10.0% |
| HOLOGIC INC | 17 | Q1 2022 | 6.5% |
| SPY US 10/21/16 P210 | 17 | Q3 2023 | 41.5% |
View Tamarack Advisers, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTIONS INC. | June 22, 2023 | 5,514,515 | 9.4% |
| IVERIC bio, Inc. | February 16, 2021 | 850,000 | 0.1% |
| Correvio Pharma Corp. | February 14, 2020 | 2,500,000 | 4.9% |
| OBALON THERAPEUTICS INC | February 14, 2020 | ? | ? |
| Correvio Pharma Corp. | February 15, 2019 | ? | ? |
| Corium International, Inc. | February 15, 2017 | 737,242 | 3.3% |
| ENDOLOGIX INC /DE/Sold out | February 15, 2017 | 0 | 0.0% |
| Imprivata IncSold out | February 15, 2017 | 0 | 0.0% |
View Tamarack Advisers, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-09 |
| 13F-HR | 2023-11-16 |
| 13F-HR | 2023-08-10 |
| SC 13D/A | 2023-06-22 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-13 |
| SC 13D/A | 2022-12-01 |
| 13F-HR | 2022-11-15 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-11 |
View Tamarack Advisers, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.